// App-Quantinova.ai

4080 : Impact of integrating insulin like growth factor-1 (IGF-1) in model for end stage liver disease (MELD) scores on predicting hepatocellular carcinoma patients survival.

Researchers

Presenter

  • Reham Abdel-Wahab

Principal Investigators

  • Sahin Lacin

  • Ahmed S Shalaby

  • Manal Hassan

  • Lianchun Xiao

  • Jeffrey Morris

  • Hesham M. Amin

  • Ahmed Omar Kaseb

Medical Centers

  • Clinical Oncology Department, Assiut University, Assiut, Egypt

  • GI Medical Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

  • Egypt

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • End-stage liver disease

  • Solid malignancies

Biomarkers

  • Insulin-like growth factor 1

Drug/Treatment

  • Mecasermin

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved